TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00330421

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: Correlative studies
Study: NCT04524299

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: chest radiation(IMRT)
Description: Patients will receive intensity modulated radiotherapy (IMRT) once a day, 5 days a week. The first stage: DT 3000 cGy / 6 FX; the second stage, DT 3500 cGy / 7 FX. Or: the first segment: DT 4000 cGy / 10 FX; the second segment DT 2400 cGy / 6 FX. The interval between two stages of radiotherapy was 4 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chest radiation(IMRT)
Description: Patients will receive intensity modulated radiotherapy (IMRT) once a day, 5 days a week. The first stage: DT 3000 cGy / 6 FX; the second stage, DT 3500 cGy / 7 FX. Or: the first segment: DT 4000 cGy / 10 FX; the second segment DT 2400 cGy / 6 FX. The interval between two stages of radiotherapy was 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy twice a week
Description: During the same period of radiotherapy, 30 mg / m2 albumin bound paclitaxel was intravenously infused twice a week for 0.5 hours, and nedaplatin 10 mg / m2 twice a week for 0.5 hours.~1. When the radiotherapy dose was 3000 cGy / 6 FX + DT 3500 cGy / 7 FX, the infusion time was D1, D4, D8 of the first stage of radiotherapy; D1, D4, D8 of the second stage of radiotherapy.~2. When the radiotherapy dose was 4000 cGy / 10 FX + DT 2400 cGy / 6 FX, the infusion time was D1, D4, D8, D11 of the first stage of radiotherapy; D1, D4, D8 of the second stage of radiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemotherapy once a week
Description: During the same period of radiotherapy, albumin bound paclitaxel (50 mg / m2) was intravenously infused once a week for 0.5 hours; nedaplatin (25 mg / m2) was intravenously infused once a week for 0.5 hours. The infusion time was D1, D8 of the first radiotherapy and D1, D8 of the second radiotherapy.
Study: NCT05676333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Study: NCT02414269

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: iCasp9M28z T cell infusions
Description: Administration through the pleural catheter- On day 0 patients will be treated with genetically modified T cells. Thirty to 60 minutes before T cell infusion, patients will be given 650 mg of acetaminophen orally and 25- 50 mg of diphenhydramine orally or intravenously, to prevent infusion-related reactions. The genetically modified T cells will be infused for at least 15 minutes and no more than 2 hours through the indwelling pleural catheter depending on the volume of the T cells. A physician will be available during the infusion. Please note, during formulation of iCasp9M28z T cells, under or over estimation of CAR modified T Cells may occur. Patient may receive an altered fractionation of the total dose or up to 35% over or under total cell dose with approval of the PI. Patients who do not have enough cells to match the current dose cohort will be treated in the cohort in which they have cells available

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: iCasp9M28z T cell infusions
Description: Administration through the pleural catheter- On day 0 patients will be treated with genetically modified T cells. Thirty to 60 minutes before T cell infusion, patients will be given 650 mg of acetaminophen orally and 25- 50 mg of diphenhydramine orally or intravenously, to prevent infusion-related reactions. The genetically modified T cells will be infused for at least 15 minutes and no more than 2 hours through the indwelling pleural catheter depending on the volume of the T cells. A physician will be available during the infusion. Please note, during formulation of iCasp9M28z T cells, under or over estimation of CAR modified T Cells may occur. Patient may receive an altered fractionation of the total dose or up to 35% over or under total cell dose with approval of the PI. Patients who do not have enough cells to match the current dose cohort will be treated in the cohort in which they have cells available

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Patients will receive cyclophosphamide intravenously (at 1.5 g/m\^2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Pembrolizumab will be given as 200 mg flat dose infusion intravenously.
Study: NCT02891200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer support program
Description: The Peer Support Program offers education and support to participants by especially trained 'peer mentors' with oversight from a social worker.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HCP support
Description: Healthcare professional (HCP) support will be provided by a trained respiratory therapist who will provide COPD self-management education and support via an in-person session and written materials .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HCP support
Description: Healthcare professional (HCP) support will be provided by a trained respiratory therapist who will provide COPD self-management education and support via an in-person session and written materials .
Study: NCT02957409

Intervention type: DRUG
Intervention: sacubitril/valsartan
Description: This study is designed as an observational, naturalistic, multicenter study in patients being treated with sacubitril/valsartan as per the Canadian product label. Treatment initiation with sacubitril/valsartan must be within the last 3 months. Sacubitril/valsartan will be used as commercially available supplies which are available as Film coated tablets in 3 dosage: 1) 24 mg sacubitril / 26 mg valsartan, 2) 49 mg sacubitril / 51 mg valsartan and 3) 97 mg sacubitril / 103 mg valsartan.
Study: NCT01548781

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Impairment-based robotic intervention for reaching function
Description: All participants will undergo 8 weeks of reaching practice in the ACT3D. Frequency and duration will be matched at three 1.5-hour sessions per week. All reaching practice will include abduction (gravity) loading standardized to the participant's motor abilities. The experimental group intervention will also include a horizontal viscous resistant element similar to pushing the arm through molasses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impairment-based robotic intervention for reaching function
Description: All participants will undergo 8 weeks of reaching practice in the ACT3D. Frequency and duration will be matched at three 1.5-hour sessions per week. All reaching practice will include abduction (gravity) loading standardized to the participant's motor abilities. The experimental group intervention will also include a horizontal viscous resistant element similar to pushing the arm through molasses.
Study: NCT04455568

Intervention type: DEVICE
Intervention: use EKG Wisdom bracelet
Description: Non-invasive Wearable Device (use EKG Wisdom bracelet)
Study: NCT02207621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13324 Ophthalmic Solution 0.02%
Description: 1 drop once daily (QD), PM, OU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol maleate Ophthalmic Solution 0.5% BID
Description: 1 drop BID, AM/PM, OU

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 drop QD, AM, OU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13324 Ophthalmic Solution 0.02% BID
Description: 1 drop BID, AM/PM, OU
Study: NCT00290745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study: NCT01197196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss Intervention
Description: Participants assigned to this condition will receive an intensive group-based lifestyle program modeled after the DPP and Look AHEAD trials. Participants will attend 16 weekly sessions involving provision of behavioral goals and strategies to modify diet and exercise behaviors in order to achieve a weight loss of at least 7% of initial body weight.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Migraine Education
Description: Participants assigned to this condition (Healthy Living for Migraine Relief \[HLMR\]) will receive basic education and didactic instruction in migraine headaches and treatments that are the standard of care. Participants will attend 4 months of weekly group lectures focused on 3 different major topic areas: 1) migraine symptomatology and pathophysiology, 2) standard abortive and preventive pharmacological treatment options, and 3) standard and alternative non-pharmacological treatment options.
Study: NCT04269499

Intervention type: DEVICE
Group type: OTHER
Intervention: QuiremSpheres®
Description: Radioembolization with QuiremSpheres® under MR imaging
Study: NCT02200913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core stabilization exercise
Description: core stabilization exercise, 2 times/week, 10 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: general trunk strengthening exercise
Description: general trunk strengthening exercise, 2 times/week, 10 weeks
Study: NCT02804568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 3831
Description: Oral capsule, daily administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 3831
Description: Oral capsule, daily administration
Study: NCT01631084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JADE
Description: Patients are booked for reviews led by the doctor-nurse-HCA team every 2-4 months, preferably in a setting different from the busy clinics in order to facilitate group education and promote peer support.~Between each follow-up visit, the nurse or HCA will contact the patient by phone or email to remind them of the appointments (e.g. medical FU visit or laboratory tests), adhere to medications and healthy lifestyles, perform self glucose monitoring and provide psychosocial support, as appropriate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DIAMOND
Description: Patients randomized to the DIAMOND group will receive usual care after the initial baseline comprehensive assessment (CA), with repeat CA at 12 and 24 months.
Study: NCT02235350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation Treatment (AOT)
Description: Participants will be asked to carefully observe at a computer screen videos depicting different daily actions. Each action will consist of 3 to 4 constituent motor acts. Each motor act will be presented for 3 minutes. As a whole, therefore, each video will be 12 minutes long. At the end of each motor act presentation, participants will be required to execute with the affected hand the observed motor sequence for 2 minutes. Each single rehabilitation session based on AOT will last 20 minutes. We will record ten daily actions for a total of ten video-clips. Participants will be presented with each video clips, twice a day, in order of complexity as judged by the experimenter. Participants will undergo 10 sessions a week, each lasting 20 minutes for 2 weeks.
Study: NCT02199795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contralaterally Controlled Neuromuscular Electrical Stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cyclic Neuromuscular Electrical Stimulation
Study: NCT00831311

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRP~T
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-IPV//PRP~T combined vaccine & Recombinant hep B vaccine
Description: 0.5 mL, Intramuscular (right and left thighs, respectively)
Study: NCT01590043

Intervention type: OTHER
Intervention: Salivary samples
Description: Each participant will give a sample of saliva through spitting for 5 minutes in a sterile tube.

Intervention type: OTHER
Intervention: Salivary samples
Description: Each participant will give a sample of saliva through spitting for 5 minutes in a sterile tube.

Intervention type: OTHER
Intervention: Salivary samples
Description: Each participant will give a sample of saliva through spitting for 5 minutes in a sterile tube.
Study: NCT02235350

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Observation of videos with no motor content (MNO)
Description: Participants will be asked to observe video clips with no specific motor content. Videos will concern scientific, geographical and historical issues. As for cases, video clips will be divided into three to four parts. At the end of each part, controls will execute the same actions as cases, in the same order. In this way cases and controls will undergo the same amount of motor practice and receive the same amount of visual stimulation, the only difference being the content of visual stimuli.
Study: NCT01552850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 1X40 mg PF-00345439 formulation A capsule with water and under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 1X40 mg PF-00345439 formulation B capsule with water and under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 1X40 mg PF-00345439 formulation C capsule with water and under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 1X40 mg PF-00345439 formulation D capsule with water and under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 40 mg oxycodone oral solution (5 mg/5 ml) with water and under fed condition
Study: NCT01982240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plecanatide
Description: Plecanatide tablets QD for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plecanatide
Description: Plecanatide tablets QD for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets QD for 12 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Bisacodyl
Description: Rescue medication
Study: NCT02592382

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Xylitol spray
Description: xylitol nasal spray will be administered to this arm three times daily for three months
Study: NCT02799966

Intervention type: DEVICE
Group type: OTHER
Intervention: Myndmove
Description: 20 sessions of 1 hour treatments with the MyndMove device (functional electrical stimulation) to the muscles of the upper limb(s), conducted 3 to 5 times per week, over 4 to 7 weeks.

Intervention type: DEVICE
Group type: OTHER
Intervention: Myndmove
Description: 20 sessions of 1 hour treatments with the MyndMove device (functional electrical stimulation) to the muscles of the upper limb(s), conducted 3 to 5 times per week, over 4 to 7 weeks.
Study: NCT00363675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional hand tests
Description: Chilren were tested after healed hand burns for functional ability.
Study: NCT02425332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat gait trainer
Study: NCT03121157

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Component Technology Based Intervention
Description: The intervention group receives two sessions of computer-delivered MI via software programmed to target adherence to medications and text messaged adherence reminders between sessions. Sessions are provided by an avatar. The intervention engages the youth with the avatar's communication of empathy, optimism, and autonomy support. The intervention focuses the youth on adherence and relevant health behaviors with feedback on adherence, asthma symptoms, and tailored education. Participants are guided in the planning process through goal setting activities. The length of the intervention sessions are about 30 minutes each, with the total duration of the visit (assessment and intervention) lasting about 1.5 hours.
Study: NCT03639701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymidine
Description: Mitochondrial DNA nucleotide precursors. Dose escalation: 130mg/kg/day x 14 days, 260 mg/kg/day x 14 days, and 400mg/kg/day as tolerated. Compounds are taken orally and divided into 3 doses daily.
Study: NCT02782702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulism Toxin Treatment
Description: Injection of 50 UI of botulism toxin for treated zone
Study: NCT02367755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol use during therapeutic hypothermia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Lorazepam use during therapeutic hypothermia
Study: NCT00441701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navarixin 1 mg
Description: Navarixin 1 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navarixin 1 mg
Description: Navarixin 1 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navarixin 10 mg
Description: Navarixin 10 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navarixin 10 mg
Description: Navarixin 10 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navarixin 10 mg
Description: Navarixin 10 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navarixin 10 mg
Description: Navarixin 10 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match navarixin
Description: Placebo to navarixin capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match navarixin
Description: Placebo to navarixin capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match navarixin
Description: Placebo to navarixin capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match navarixin
Description: Placebo to navarixin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match navarixin
Description: Placebo to navarixin capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match navarixin
Description: Placebo to navarixin capsules
Study: NCT02547142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Palliative Care
Description: Metastatic esophageal cancer patients that receive early palliative care along with standard oncological care
Study: NCT01311765

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Duration of antibiotic therapy limited to 8 days
Description: Initiation of adequate empiric antibiotics for postoperative peritonitis within 24 hours after surgery and up to 8 days. At randomisation performed on day 8, the patients assigned to the 8-day group (short-course group) stop their treatment
Study: NCT00441701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Salbutamol/albuterol - 2 puffs of salbutamol/albuterol approximately every 4 hours as needed for dyspnea relief

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Salbutamol/albuterol - 2 puffs of salbutamol/albuterol approximately every 4 hours as needed for dyspnea relief

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Salbutamol/albuterol - 2 puffs of salbutamol/albuterol approximately every 4 hours as needed for dyspnea relief

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue medication
Description: Salbutamol/albuterol - 2 puffs of salbutamol/albuterol approximately every 4 hours as needed for dyspnea relief
Study: NCT02236845

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lacrima Medical Device and sham comparator

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Lacrima Medical Device and sham comparator
Study: NCT00441701

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue medication
Description: Salbutamol/albuterol - 2 puffs of salbutamol/albuterol approximately every 4 hours as needed for dyspnea relief

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue medication
Description: Salbutamol/albuterol - 2 puffs of salbutamol/albuterol approximately every 4 hours as needed for dyspnea relief

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Salbutamol/albuterol - 2 puffs of salbutamol/albuterol approximately every 4 hours as needed for dyspnea relief

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Salbutamol/albuterol - 2 puffs of salbutamol/albuterol approximately every 4 hours as needed for dyspnea relief

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Salbutamol/albuterol - 2 puffs of salbutamol/albuterol approximately every 4 hours as needed for dyspnea relief

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue medication
Description: Salbutamol/albuterol - 2 puffs of salbutamol/albuterol approximately every 4 hours as needed for dyspnea relief
Study: NCT06315647

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DGT vs TPS vs Precut and fistulotomy in Difficult CBD cannulation
Description: comparison between different technique in difficult CBD cannulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DGT vs TPS vs Precut and fistulotomy in Difficult CBD cannulation
Description: comparison between different technique in difficult CBD cannulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DGT vs TPS vs Precut and fistulotomy in Difficult CBD cannulation
Description: comparison between different technique in difficult CBD cannulation